Using advanced imaging and data analysis to predict treatment responses in lung cancer patients
Prospective validation of a radiomics-based multi-modal predictive model for metastatic non-small cell lung cancer patients treated with PD-1 immunotherapy
This study is looking to create a smarter way to predict which patients with advanced lung cancer will benefit from a specific immunotherapy treatment, using a mix of advanced imaging and lab tests to help doctors make better choices for their patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Onc.ai, INC. NIH-funded |
| Lab location | 1 site (San Carlos, United States) |
| Project ID | NIH-11007396 on NIH RePORTER |
What this research studies
This research aims to develop a new predictive model that combines advanced imaging techniques with clinical and genomic data to better identify which patients with metastatic non-small cell lung cancer will respond to PD-1 immunotherapy. By utilizing machine learning and computer vision on CT scans, alongside routine lab tests, the study seeks to improve patient selection for this treatment, which currently has low response rates. The goal is to create a more effective and personalized approach to cancer therapy, potentially leading to better outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic non-small cell lung cancer who are considering or currently undergoing PD-1 immunotherapy.
Not a fit: Patients with other types of cancer or those not eligible for PD-1 immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly enhance the ability to predict which patients will benefit from PD-1 immunotherapy, leading to improved treatment outcomes and reduced unnecessary costs and side effects.
How similar studies have performed: While there have been various attempts to predict responses to PD-1 immunotherapy, this radiomics-based approach is novel and has not been extensively tested in this context.
Where this research is happening
San Carlos, United States
- Onc.ai, INC. — San Carlos, United States (Active)
Researchers
- Principal investigator: Jordan, Petr — Onc.ai, INC.
- Study coordinator: Jordan, Petr
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.